Proficio Capital Partners LLC Acquires 219,162 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Proficio Capital Partners LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 92,865.3% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 219,398 shares of the biopharmaceutical company’s stock after acquiring an additional 219,162 shares during the quarter. Proficio Capital Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $156,284,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Nvwm LLC boosted its holdings in Regeneron Pharmaceuticals by 1.4% in the third quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock worth $1,039,000 after acquiring an additional 14 shares in the last quarter. Howe & Rusling Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 3.4% during the 3rd quarter. Howe & Rusling Inc. now owns 462 shares of the biopharmaceutical company’s stock valued at $486,000 after acquiring an additional 15 shares during the last quarter. Willner & Heller LLC grew its position in Regeneron Pharmaceuticals by 3.9% in the 4th quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock worth $284,000 after purchasing an additional 15 shares during the period. OLD Second National Bank of Aurora lifted its holdings in shares of Regeneron Pharmaceuticals by 0.5% during the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock valued at $2,025,000 after buying an additional 15 shares during the period. Finally, SteelPeak Wealth LLC boosted its stake in shares of Regeneron Pharmaceuticals by 1.5% in the 3rd quarter. SteelPeak Wealth LLC now owns 1,108 shares of the biopharmaceutical company’s stock worth $1,165,000 after buying an additional 16 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $706.94 on Thursday. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The stock has a market cap of $77.29 billion, a price-to-earnings ratio of 18.47, a PEG ratio of 2.34 and a beta of 0.08. The business has a 50 day moving average price of $698.68 and a 200 day moving average price of $874.30.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the previous year, the firm posted $11.86 EPS. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Truist Financial cut their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Piper Sandler decreased their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Finally, Wells Fargo & Company lowered their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.